Alnylam Pharmace. buy StockNews.com
Start price
02.11.25
/
50%
€395.60
Target price
02.11.26
-
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 02.11.26. The prediction end date can be changed by StockNews_com at any time.Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | - |
| iShares Core DAX® | -0.998% |
| iShares Nasdaq 100 | 2.834% |
| iShares Nikkei 225® | 5.533% |
| iShares S&P 500 | 1.544% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat